Health benefits of combined oral contraceptives - a narrative review.

Purpose: This review presents an update of the non-contraceptive health benefits of the combined oral contraceptive pill.

Methods: We conducted a literature search for (review) articles that discussed the health benefits of combined oral contraceptives (COCs), in the period from 1980 to 2023.

Results: We identified 21 subjective and/or objective health benefits of COCs related to (i) the reproductive tract, (ii) non-gynaecological benign disorders and (iii) malignancies.

Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but affected thyroid function.

Objective: To assess the safety, pharmacokinetics, and pharmacodynamics of MK-8389.

Design: Double-blind, placebo-controlled, parallel-group, ascending dose study.

Setting: Two clinical research organizations.

Pharmacokinetic profile of nomegestrol acetate and 17β-estradiol after multiple and single dosing in healthy women.

Background: The pharmacokinetics of the monophasic oral contraceptive nomegestrol acetate (NOMAC) plus 17β-estradiol (E(2)) were investigated after a single dose and multiple dosing.

Study Design: NOMAC/E2 (2.5 mg/1.

Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations.

Asenapine is indicated for treatment of schizophrenia in the United States and acute treatment of manic or mixed episodes, as monotherapy (United States and European Union) or adjunct therapy (United States only), associated with bipolar I disorder. It is extensively metabolized; the 2 main metabolites are asenapine N-glucuronide and N-desmethyl-asenapine. The authors investigated the pharmacokinetic interactions between asenapine and valproate in an open-label, randomized, 2-way crossover study.